19 October 2021

New research uncovers growth dynamics of pancreatic cancer

Bianca-Olivia Nita

Bianca-Olivia Nita

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease and patients diagnosed with PDAC have a very poor prognosis. It has been speculated that a rare population of cancer stem cells (CSCs) are responsible for tumor growth, therapy resistance, and rapid metastatic progression in PDAC. The purported CSC populations were discovered by in vitro clonogenic assays and transplantation assays in mice. However, their relevance in established PDAC tissue has not been determined. Importantly these assays were mostly dependent on the expression of a specific marker, therefore the functionality of cell populations not expressing these markers remained untested. A new study by Oncode Investigator Louis Vermeulen and co-investigators Sophie Lodestijn and Maarten Bijlsma (all Amsterdam UMC), published today in Cell Reports, changes that. Their results can have important implications for the treatment of PDAC.

In the study, the researchers used a method their group previously established, in which tumor cells were randomly labelled within an established tumor. The elegance of this method is the independence of a specific marker, in this way the properties of all tumor cells could be analyzed. Using the resulting clonal data in combination with quantitative modelling of tumor expansion, they were able to uncover the tissue growth dynamics of PDAC.

What they found is that all PDAC cells display clonogenic potential within an expanding tumor. Furthermore, the tumor cells that were in close proximity to activated cancer-associated fibroblasts showed higher clonogenicity. This indicates that the microenvironment drives clonogenic activity of PDAC cells. Indeed, inhibiting the stroma by Hedgehog pathway inhibition altered the tumor growth mode, resulting in inhibition of excessive clonal expansion (fewer large clones). This implies that tumor-stroma crosstalk shapes tumor growth dynamics and clonal architecture in PDAC.

“I hope our fundamental work will contribute to improved therapies for this lethal disease in the future” says Oncode Investigator Louis Vermeulen. The findings can have important implications for the treatment of PDAC. For instance, targeted therapy of cancer cells, based on phenotypic properties, are likely to fail, because non-clonogenic cells will become clonogenic when they gain access to the right niche, like being in close contact to activated fibroblasts. Therefore, changing the favourable clonogenic niche to a clonogenic restraining niche might be more effective to target cancer tissue and prevent regrowth of the malignancy by remaining cancer cells.

This work was supported by Oncode, Amsterdam UMC, KWF and the European Research Council.

Other News

Oncode Icons Square 01
Oncode-PACT proposal submitted to Growth Fund
Oncode Institute is proud to announce that the Ministry of Economic Affairs and Climate Policy formally decided to submit the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) proposal to the Growth Fund (Groeifonds) Commission on November 1st, 2021.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Clinic
Clinical trial with new lung cancer vaccine started
Last week a new clinical trial with a vaccine against non-small cell lung cancer started at Erasmus MC. The vaccine teaches the immune system of lung cancer patients to recognize and clear tumor cells. Developed in the lab of Oncode Investigator Sjoerd van der Burg at Leiden University Medical Center, the technology may offer relief to a large proportion of the nearly 10,000 patients who receive this diagnosis each year.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Picture2
A wrap-up of the Clinical Workshop Melanoma: looking into present approaches and what the future looks like
Due to restrictions linked to the pandemic, the Clinical Workshop Melanoma had to be postponed from last year to October this year. The restrictions relaxed and finally being able to come together, the long-expected event could take place. We now look back at a successful workshop that took place on the 5th of October at the Oncode office in Utrecht. The goal of the event was to bring together clinicians and clinical and basic researchers to discuss the tumor type melanoma, and to discuss current trends and unmet needs both within the clinic and in (clinical) research. The workshop aimed to also explore how basic research can address these unmet clinical needs and to stimulate new collaborations through translational and clinical projects.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>